United States — Food and Drug Administration & Regeneron Pharmaceuticals

United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.

Regeneron Pharmaceuticals: Regeneron is a key player in the antibody therapeutics market, benefiting from the projected market growth.

United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.

Regeneron Pharmaceuticals: Co-developer of injectable PCSK9 inhibitor Praluent; may see reduced demand.

United States — Food and Drug Administration: The United States — Food and Drug Administration has approved Inmazeb, a combination of antibodies, to treat Zaire Ebolavirus infection, which Regeneron Pharmaceuticals has donated for potential use in the current outbreak.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.

United States — Food and Drug Administration: The United States — Food and Drug Administration>>> (FDA) is the regulatory body reviewing Alvogen's resubmitted applications for AVT05 and AVT06. Their decision will determine the market entry of these biosimilars in the United States>>>.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals>>> owns the trademark for Eylea, the reference product for Alvogen>>>'s AVT06 biosimilar. The potential market entry of AVT06 could introduce competition to Regeneron Pharmaceuticals>>>'s product.

United States — Food and Drug Administration: The FDA conducted and closed the inspection, classifying the site as VAI, and is reviewing Alvogen's BLAs; its actions directly affect Alvogen's regulatory progress.

Regeneron Pharmaceuticals: Holder of Eylea trademark; Alvogen's biosimilar AVT06 targets Eylea, but no direct impact from this event.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.